Selecta Biosciences Inc
NASDAQ:SELB
Selecta Biosciences Inc
NASDAQ:SELB
Price:
0.7465 USD
5.14%
Updated:
May 1, 2024
Section:
Relative Value
The Relative Value of one
SELB
stock under the Base Case scenario is
1.0548
USD.
Compared to the current market price of 0.7465 USD,
Selecta Biosciences Inc
is
Undervalued by 29%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SELB
Relative Value
Base Case
1.0548
USD
Undervaluation 29%
Valuation Multiples
Multiples Across Competitors
SELB Competitors Multiples
Selecta Biosciences Inc Competitors
Selecta Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Selecta Biosciences Inc
NASDAQ:SELB
|
114.5m USD | 2.4 | -3.3 | -0.4 | -0.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.2B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.7B USD | 5.2 | 21.8 | 16.3 | 24.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.2B USD | 10.3 | 28 | 22.3 | 23.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.4B USD | 7.4 | 24.6 | 16.3 | 17.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.7B AUD | 6.1 | 35 | 21.2 | 26.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.2B USD | 3 | 14.3 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.1B USD | 6.2 | -8.9 | -9.4 | -8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.8 | 14.5 | 18 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
